Atovaquone inhibits the glucuronidation of zidovudine, but this only resulted in a small 25% decrease in its clearance in one study, and no significant pharmacokinetic changes in another.
The increased
plasma levels of zidovudine are unlikely to be clinically significant. Nevertheless, the manufacturers recommend regular monitoring for zidovudine- associated adverse effects, particularly if
atovaquone suspension is used, as this achieves higher
atovaquone levels.